A
Accuryn Medical
Patient monitoring platform that detects sepsis and fluid overload in ICU patients via urinary catheter
About Accuryn Medical
Accuryn Medical, formerly known as Potrero Medical Inc., is a predictive health company founded in 2011 and headquartered in Hayward, California. The company emerged from the medical device incubator Theranova, with a focus on addressing significant challenges in healthcare. A key milestone was the successful restructuring and completion of an over-subscribed equity offering in early 2024, which provided a clean balance sheet and substantial funding.
The company operates in the critical care monitoring market, providing a solution to the challenges of Acute Kidney Injury (AKI), a condition affecting a large percentage of ICU patients and responsible for significant mortality and healthcare costs. Accuryn's business model centers on selling its proprietary monitoring system to hospitals and critical care units. The company's revenue is generated from these sales, and it has shipped over 100,000 catheters nationwide. Leadership has seen recent transitions, with Rich Keenan and Sanjay Banerjee appointed as Co-CEOs in April 2024, followed by Todd Dunn, a former customer with a background at GE Healthcare and Atrium Health, taking the CEO role.
Accuryn Medical's core product is the Accuryn® Monitoring System, which transforms a standard Foley catheter into a smart-sensing diagnostic tool. This system provides real-time, continuous monitoring of vital signs including urine output (UO), intra-abdominal pressure (IAP), and core body temperature. A key feature is its active drain line clearance, which automatically prevents blockages to ensure accurate UO measurement, a critical factor in detecting kidney distress. The system received FDA 510(k) clearance in 2016 and the CE Mark in Europe in 2019. Further enhancing its capabilities, the FDA granted Breakthrough Device Designation in 2022 for the company's AKI Predict machine learning algorithm, designed for the advanced prediction of AKI. This allows the system to provide alerts for potential kidney injury hours earlier than traditional methods like serum creatinine tests, enabling earlier clinical intervention.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 70.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Predictive Analytics, Biotechnology, Kidney
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Nanotech, Recognition Technology
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $6.5M | $133M | Undisclosed | ↗ |
| LATE VCOther financing | Apr 2023 | $18M | $71M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Accuryn Medical is 3.4K monthly website visits, down 5.6% over the last three months. Accuryn Medical's team grew 2.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Accuryn Medical in the Hayward ecosystem
The Accuryn Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Green Park & Golf Ventures
Series B and later3 investors entered at this stage
GT Healthcare
Sonder Capital
Sonder
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accuryn Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accuryn Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









